Comparative Pharmacology
Head-to-head clinical analysis: AMPHETAMINE SULFATE versus APTENSIO XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHETAMINE SULFATE versus APTENSIO XR.
AMPHETAMINE SULFATE vs APTENSIO XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases presynaptic release of dopamine and norepinephrine, blocks reuptake, and inhibits monoamine oxidase, resulting in CNS stimulation.
Central alpha-2 adrenergic agonist that selectively stimulates alpha-2 adrenergic receptors in the brain stem, reducing sympathetic outflow and decreasing peripheral vascular resistance, heart rate, and blood pressure.
5–60 mg/day orally in 1–3 divided doses, initial 5 mg once or twice daily, increase by 5 mg weekly.
Oral, 20 mg once daily in the morning; may increase by 10–20 mg/day at 3-day intervals up to a maximum of 60 mg/day.
None Documented
None Documented
Terminal elimination half-life: 10-13 hours in adults with acidic urine; prolonged to 16-34 hours with alkaline urine. In children, half-life is typically shorter (6-8 hours).
The terminal elimination half-life of methylphenidate (IR and extended-release) is approximately 3-4 hours in children and 3.5-5 hours in adults. For Aptensio XR, the half-life is about 4-5 hours, supporting twice-daily dosing.
Renal excretion of unchanged amphetamine (approximately 30-40%) and its metabolites; urinary pH-dependent: acidic urine enhances elimination (up to 70% unchanged), alkaline urine reduces it. Minor biliary/fecal elimination (<10%).
Methylphenidate is primarily excreted renally as metabolites (80-90%), with 1-3% excreted unchanged. Biliary/fecal elimination accounts for <5%.
Category D/X
Category C
CNS Stimulant
CNS Stimulant